payments and research output, revealing a connection between receiving payments and increased scholarly impact. [3] [4] [5] [6] [7] In the field of ophthalmology, industry payments have been associated with distinct patterns in prescribing of antivascular endothelial growth factor (VEGF) agents, prompting questions about the impact of these payments on ophthalmologists.
8,9
To broaden the understanding of industry payments to ophthalmologists, we conducted a comprehensive analysis of Open Payments data for every academic ophthalmologist in the United States, examining associations between industry support and scholarly impact. We also analyzed the influence of subspecialty, gender, academic rank, type of degree, and additional degree(s) (e.g., MBA, MPH) on scholarly output. As ophthalmologists with high scholarly impact are considered academic leaders and are often asked to serve on guideline committees or lead practice-determining clinical trials, an understanding of these dynamics is a critical step toward increasing transparency and research integrity in ophthalmology.
Methods Study Sample
Our sample consisted of ophthalmology faculty included on publicly available web sites of all 117 accredited ophthalmology residency programs in the continental United States, as listed by the Accreditation Council for Graduate Medical Education. 10 Using the web sites for each of these residency programs, the following information was extracted for each ophthalmologist: name, gender, primary medical degree (MD, DO, MD/PhD), presence of additional degree(s) (binary variable; included degrees such as MBA, MPH, and MHS), and academic rank (assistant professor, associate professor, full professor). Subspecialty data were collected from the American Academy of Ophthalmologists (AAO) "Find an Ophthalmologist" database and from faculty webpages.
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We excluded faculty without an MD or DO degree, as reporting requirements apply to physicians only. 12 We also excluded ophthalmologists whose title was not one of the following: assistant professor, associate professor, or professor. Ophthalmologists whose appointment specified a primarily clinical role (e.g., "Clinical Associate Professor") were excluded, as we assumed that research may not be a primary component of their responsibilities. We also excluded ophthalmology faculty members from military training programs and from programs located outside of the continental United States. Ophthalmologists whose most recent publication was more than 10 years before 2016 were also excluded, because we assumed that these ophthalmologists were no longer actively involved in research. Finally, ophthalmologists for whom subspecialty data could not be located were excluded from the subspecialty analysis only.
Payments to Physicians
Industry payments to ophthalmologists were identified using the CMS Open Payments Database for the year 2016, 2 which was the most recent year available at the time of data collection for this study. The Open Payments Database makes information about financial relationships between physicians and certain healthcare manufacturers publicly available. Payments of the following types were recorded for each ophthalmologist: general payments (i.e., payments not associated with research), research payments (i.e., payments associated with a research agreement or protocol), physician ownership or investment interest (i.e., value of ownership or investment interest in certain healthcare manufacturers), and associated research funding (i.e., payments to a research institution that name the physician as a principal investigator). 13 Total payments received by each ophthalmologist were divided into the following payment categories, consistent with those used in a previous analysis of the Open Payments data: less than $100, $100 to 1,000, $1,000 to 10,000, $10,000-100,000, and greater than $100,000. 4 General payments were also grouped into the following types: food and beverage, education, consulting, speaker at a Continuing Education Program (CEP), speaker at a non-CEP, travel and lodging, honorarium, entertainment, gifts, and other (e.g., charitable contributions, royalty, or license fees).
Outcome Variables
To assess the overall scholarly impact of each ophthalmologist, bibliometric data were extracted using the "Author Search Tool" from Scopus.
14 Scopus is a database of peerreviewed literature with information about citations. The following data were extracted for each ophthalmologist: Hirsch index (H-index), total number of documents, total citations, and range of publication activity (in years). H-index is a validated marker of scholarly impact, defined by having published h publications with at least h citations per publication. 15 For example, a physician with an H-index of 30 has published at least 30 publications with at least 30 citations each. This metric has been shown to be a better measure of the overall quality and quantity of a scientist's research than other variables, such as total citations or total publications.
16

Statistical Analysis
Descriptive statistics were used to characterize the sample. We used analysis of variance and two-sided unpaired t-tests for comparison of continuous variables. A p-value of 0.05 was used for all statistical tests. All analyses were performed using Stata 15.0 and outputs were displayed with GraphPad Prism 7.0. Institutional Review Board approval was obtained from the Yale University Institutional Review Board.
Payments to Academic Ophthalmologists
Of the 1,653 academic ophthalmologists in our sample, 1,225 (74%) received industry payments in 2016, totaling $35.0 million. The majority of this funding was in the form of general payments ($18.9 million, 54%) and associated research payments ($13.1 million, 37%); the remaining payments were physician ownership ($2.8 million, 8%) and direct research payments ($0.2 million, <1%). Among academic ophthalmologists who received any form of industry payment, the median payment amount was $265 (interquartile range, $81-4,341), and the mean was $28,582. Of these ophthalmologists, 352 (29%) received less than $100, 468 (38%) received between $100 and 1,000, 172 (14%) received between $1,000 and 10,000, 152 (12%) received between $10,000 and 100,000, and 81 (7%) received greater than $100,000 (►Table 2). Payments totaling more than $10,000 were received by males more commonly than females (22 vs13%) , and by full and associate professors more commonly than assistant professors (27 vs 23% vs 8%, respectively). Ophthalmologists in the following subspecialties most commonly received payments totaling more than $10,000: surgical retina (33%), glaucoma (26%), uveitis/ immunology (24%), cataract/anterior segment (22%), and other (42%). There was no statistically significant difference between the mean H-index of academic ophthalmologists receiving any industry payments and those not receiving any payments (p ¼ 0.68). However, among academic ophthalmologists who did receive industry payments, there was a significant difference in H-index by payment category (p < 0.001) (►Fig. 1). The mean H-index was 12.6 for ophthalmologists receiving less than $100, 12.2 for those receiving between $100 and 1,000, 18.8 for those receiving between $1,000 and 10,000, 21.3 for those receiving between $10,000 and 100,000, and 29.4 for those receiving greater than $100,000. These differences remained statistically significant when analyzing other bibliometric indicators, including total number of publications (p < 0.001) and total number of citations (p < 0.001).
In analysis examining general payments only, there was a significant difference in mean H-index by general payment amount (p < 0.001). The most common general payment type was food and beverage, with 1,100 ophthalmologists (94% of ophthalmologists receiving any general payment) receiving this type of payment (►Table 3). Additionally, there was a significant difference between the mean H-index of ophthalmologists receiving greater than $1,000 versus less shown that H-index varies by academic rank and fellowship, 17 our study is the first to investigate the impact of industry funding on scholarly impact. In addition to confirming these differences in scholarly impact by academic rank and subspecialty, our analysis also extends these findings to show that industry funding modulates these associations. Within subspecialties such as cornea/eternal disease, glaucoma, oculoplastics, pediatric ophthalmology/strabismus, and surgical retina, ophthalmologists receiving greater than $1,000 in industry funding had significantly higher mean H-index than those receiving less than $1,000. We did not observe these differences in other subspecialties, likely due to limited sample size. For example, only 11 of the 25 ophthalmic pathologists in our sample received payments, and only two of these received greater than $1,000 in industry payments; ophthalmic pathologists may also be trained through pathology rather than ophthalmology. Our findings are also consistent with research about gender differences in industry funding of ophthalmologists, again demonstrating that female ophthalmologists receive industry payments considerably less commonly than men and in lower quantities. 18, 19 Finally, our analyses mirror the results of a previous study that identified an association between National Institutes of Health (NIH) funding and H-index of ophthalmologists.
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There are several possible explanations for the association between industry funding and scholarly impact among academic ophthalmologists. Pharmaceutical companies may seek influential ophthalmologists (often referred to as "key opinion leaders") for speaking and consulting engagements, preferentially making payments to ophthalmologists with high scholarly impact. Additionally, ophthalmologists' research may benefit indirectly from industry payments through access to other academic leaders. For example, an ophthalmologist who is paid for a speaking engagement may meet potential research collaborators and gain exposure to new research ideas, which could ultimately lead to increased scholarly impact. Finally, given that consulting fees and travel/lodging represented two of the largest categories of general payments in our analysis, it is possible that ophthalmologists involved in consulting engagements benefit from increased access to research opportunities in collaboration with industry researchers, ultimately increasing their scholarly output.
Given the growing scrutiny of the pharmaceutical industry's impact on medicine, our findings have important implications for the field of academic ophthalmology. Many academic publications and general media outlets have focused on the ways that the pharmaceutical industry can impact prescribing, 21 disease definitions, 22 healthcare expenditures, 23 and medical education. 24, 25 In ophthalmology, industry payments have been shown to impact VEGF prescribing; 8, 9 however, a study of ophthalmology residents showed that while the majority of trainees interact with pharmaceutical representatives, these trainees commonly feel that they are not susceptible to the influence of pharmaceutical promotions. 26 This discrepancy suggests that clinicians may be subconsciously influenced by industry contributions, and warrants further investigation. Further, industry payments may influence patient perceptions of ophthalmologists: a recent study showed that patients commonly disapprove of their ophthalmologists receiving $100 or more in industry payments of any kind. 27 In our study, the majority of ophthalmologists received this level of payment. Many professional organizations, including industry organizations such as the Pharmaceutical Research and Manufacturers of America 28 and physician organizations such as the AAO, have responded to these concerns by publishing guidance on relationships between industry and healthcare professionals and by promoting transparency through requiring conflict of interest (COI) disclosures. For example, AAO requires that anyone who is in a "position to influence content" must disclose their COIs. 29 This policy requires individuals such as speakers and reviewers to disclose if they have a "financial relationship with a commercial interest and the opportunity to affect the content of CME (Continuing Medical Education) about the products or services of that commercial interest." However, to our knowledge, there are no reporting requirements for payments that are unrelated to an individual's current AAO engagement but that may have influenced that individual's scholarly productivity, such as the nonresearch payments analyzed in our study. Our findings also have implications for career development in ophthalmology, given the emphasis on producing high-impact scholarly work to achieve academic career progression. Because metrics such as number of publications and citation frequency have historically been used to support academic promotion decisions, knowledge of how industry funding impacts these outcomes is an essential component of understanding career development in academic ophthalmology. There are several limitations to our study. First, our study was not designed to identify a causal relationship between industry funding and scholarly impact. Our study examines an association between these factors, and therefore cannot determine whether industry payments result in higher H-index or whether an ophthalmologist's research productivity leads to greater industry payments, or a combination of both. Second, while the H-index is a widely used surrogate for scholarly productivity, it has several limitations: it does not give credit to heavily cited articles, it is not an optimal tool for making comparisons across different types of research (e.g., basic science research vs retrospective epidemiological research), it favors researchers who publish in developed fields and clinical trials, and it can be artificially inflated by self-citation. 30 Third, the Scopus database occasionally splits a single author's information into multiple profiles, often after an author switches institutions. In these cases, we chose the profile with the highest H-index, although this approach still underestimates the author's scholarly productivity. Finally, our analysis was limited to industry support and did not control for other sources of funding, such as NIH grants, which are associated with greater scholarly impact.
In summary, our analysis demonstrates a significant association between industry payments and scholarly impact, even after adjusting for gender, academic rank, and subspecialty. While our study cannot identify a causal relationship, our findings do highlight the important role of industry funding in academic ophthalmology research. As the Open Payments Program accumulates additional data and COI transparency increases, future research should further characterize the relationship between industry funding and scholarly impact in the field of ophthalmology. Fig. 2 Mean H-index of ophthalmologists receiving <$1,000 versus >1,000 of industry payments. Notes: Mean H-index of academic ophthalmologists receiving less than versus more than $1,000 in total industry payments, stratified by (top) gender, academic rank, degree (s), and (bottom) subspecialty. Ophthalmologists whose only degree was DO were excluded from the degree analysis due to limited sample size (n ¼ 8). Ophthalmologists for whom subspecialty data could not be found were excluded from the subspecialty analysis. Error bars indicate standard error of mean. Statistical significance indicated by
